vs
Side-by-side financial comparison of Sanara MedTech Inc. (SMTI) and STEM, INC. (STEM). Click either name above to swap in a different company.
STEM, INC. is the larger business by last-quarter revenue ($47.1M vs $27.5M, roughly 1.7× Sanara MedTech Inc.). Sanara MedTech Inc. runs the higher net margin — -5.9% vs -33.9%, a 28.0% gap on every dollar of revenue. On growth, Sanara MedTech Inc. posted the faster year-over-year revenue change (4.6% vs -15.6%). Over the past eight quarters, STEM, INC.'s revenue compounded faster (36.1% CAGR vs 21.8%).
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
SMTI vs STEM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.5M | $47.1M |
| Net Profit | $-1.6M | $-16.0M |
| Gross Margin | 93.2% | 48.9% |
| Operating Margin | 23.5% | -17.7% |
| Net Margin | -5.9% | -33.9% |
| Revenue YoY | 4.6% | -15.6% |
| Net Profit YoY | 5.3% | 68.8% |
| EPS (diluted) | $-0.32 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $27.5M | $47.1M | ||
| Q3 25 | $26.3M | $38.2M | ||
| Q2 25 | $25.8M | $38.4M | ||
| Q1 25 | $23.4M | $32.5M | ||
| Q4 24 | $26.3M | $55.8M | ||
| Q3 24 | $21.7M | $29.3M | ||
| Q2 24 | $20.2M | $34.0M | ||
| Q1 24 | $18.5M | $25.5M |
| Q4 25 | $-1.6M | $-16.0M | ||
| Q3 25 | $-30.4M | $-23.8M | ||
| Q2 25 | $-2.0M | $202.5M | ||
| Q1 25 | $-3.5M | $-25.0M | ||
| Q4 24 | $-1.7M | $-51.1M | ||
| Q3 24 | $-2.9M | $-148.3M | ||
| Q2 24 | $-3.5M | $-582.3M | ||
| Q1 24 | $-1.8M | $-72.3M |
| Q4 25 | 93.2% | 48.9% | ||
| Q3 25 | 92.9% | 35.5% | ||
| Q2 25 | 92.5% | 33.4% | ||
| Q1 25 | 92.2% | 32.4% | ||
| Q4 24 | 91.4% | -4.4% | ||
| Q3 24 | 90.8% | 21.2% | ||
| Q2 24 | 90.0% | 27.6% | ||
| Q1 24 | 89.8% | -95.0% |
| Q4 25 | 23.5% | -17.7% | ||
| Q3 25 | 11.2% | -33.6% | ||
| Q2 25 | -0.1% | -34.8% | ||
| Q1 25 | -8.9% | -65.0% | ||
| Q4 24 | 18.6% | -84.4% | ||
| Q3 24 | 3.6% | -493.2% | ||
| Q2 24 | -14.3% | -1705.5% | ||
| Q1 24 | -8.3% | -267.0% |
| Q4 25 | -5.9% | -33.9% | ||
| Q3 25 | -115.5% | -62.2% | ||
| Q2 25 | -7.8% | 527.8% | ||
| Q1 25 | -15.1% | -76.9% | ||
| Q4 24 | -6.5% | -91.6% | ||
| Q3 24 | -13.2% | -506.3% | ||
| Q2 24 | -17.4% | -1712.6% | ||
| Q1 24 | -9.5% | -283.9% |
| Q4 25 | $-0.32 | $-4.40 | ||
| Q3 25 | $-3.40 | $-2.84 | ||
| Q2 25 | $-0.23 | $-1.79 | ||
| Q1 25 | $-0.41 | $-0.15 | ||
| Q4 24 | $-0.18 | $-15.29 | ||
| Q3 24 | $-0.34 | $-18.24 | ||
| Q2 24 | $-0.41 | $-71.81 | ||
| Q1 24 | $-0.21 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.6M | $48.9M |
| Total DebtLower is stronger | $46.0M | — |
| Stockholders' EquityBook value | $5.9M | $-249.4M |
| Total Assets | $72.9M | $308.9M |
| Debt / EquityLower = less leverage | 7.74× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.6M | $48.9M | ||
| Q3 25 | $14.9M | $43.1M | ||
| Q2 25 | $17.0M | $40.8M | ||
| Q1 25 | $20.7M | $58.6M | ||
| Q4 24 | $15.9M | $56.3M | ||
| Q3 24 | $16.3M | $75.4M | ||
| Q2 24 | $6.2M | $89.6M | ||
| Q1 24 | $2.8M | $112.8M |
| Q4 25 | $46.0M | — | ||
| Q3 25 | $45.1M | — | ||
| Q2 25 | $44.2M | — | ||
| Q1 25 | $43.4M | — | ||
| Q4 24 | $30.7M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $14.4M | — | ||
| Q1 24 | $9.7M | — |
| Q4 25 | $5.9M | $-249.4M | ||
| Q3 25 | $6.1M | $-235.7M | ||
| Q2 25 | $35.4M | $-214.1M | ||
| Q1 25 | $36.7M | $-417.5M | ||
| Q4 24 | $39.4M | $-398.4M | ||
| Q3 24 | $39.8M | $-344.1M | ||
| Q2 24 | $41.7M | $-203.2M | ||
| Q1 24 | $43.3M | $371.6M |
| Q4 25 | $72.9M | $308.9M | ||
| Q3 25 | $71.1M | $362.6M | ||
| Q2 25 | $98.8M | $379.2M | ||
| Q1 25 | $96.4M | $405.1M | ||
| Q4 24 | $88.1M | $437.4M | ||
| Q3 24 | $88.5M | $537.8M | ||
| Q2 24 | $73.4M | $691.5M | ||
| Q1 24 | $70.9M | $1.3B |
| Q4 25 | 7.74× | — | ||
| Q3 25 | 7.33× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 1.18× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.22× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.9M | $8.2M |
| Free Cash FlowOCF − Capex | $3.9M | — |
| FCF MarginFCF / Revenue | 14.0% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.9M | $8.2M | ||
| Q3 25 | $2.2M | $11.4M | ||
| Q2 25 | $2.7M | $-21.3M | ||
| Q1 25 | $-2.0M | $8.5M | ||
| Q4 24 | $932.0K | $-14.7M | ||
| Q3 24 | $2.1M | $-9.4M | ||
| Q2 24 | $-1.4M | $-11.9M | ||
| Q1 24 | $-1.6M | $-621.0K |
| Q4 25 | $3.9M | — | ||
| Q3 25 | $1.1M | — | ||
| Q2 25 | $902.7K | — | ||
| Q1 25 | $-3.7M | — | ||
| Q4 24 | $859.9K | — | ||
| Q3 24 | $2.0M | — | ||
| Q2 24 | $-1.5M | — | ||
| Q1 24 | $-1.7M | — |
| Q4 25 | 14.0% | — | ||
| Q3 25 | 4.2% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | -15.9% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 9.4% | — | ||
| Q2 24 | -7.3% | — | ||
| Q1 24 | -9.0% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | 7.4% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
STEM
Segment breakdown not available.
